細胞遊離DNA（cfDNA）検査の世界市場レポート 2025年

細胞遊離DNA（cfDNA）検査市場規模は、今後数年間で飛躍的な成長が見込まれます。2029年にはCAGR23.9％で255億6,000万米ドルに成長します。予測期間の成長は、個別化医療へのシフト、ヘルスケアインフラの強化、高齢化とがん罹患率の増加、精密医療の採用の増加、リキッドバイオプシー技術の認知度と受容度の向上、cfDNA研究への投資と資金調達の増加などに起因すると考えられます。予測期間における主な動向としては、リキッドバイオプシー技術の採用、次世代シーケンス（NGS）技術の進歩、cfDNA検査におけるAIと機械学習の統合、ポイントオブケアcfDNA検査の開発、データ保存と解析のためのクラウドベースプラットフォームの導入などが挙げられます。

がんの有病率の増加は、将来的に無細胞DNA（cfDNA）検査市場の成長を促進すると予想されます。がんは、体内での異常な細胞の増殖と拡散を特徴とする複雑な疾患群を包含します。これらの細胞は正常組織に侵入し、損傷を与える可能性があり、放置すれば重大なリスクをもたらします。がん罹患率の増加は、人口の高齢化、ライフスタイルの変化、環境の影響、検出・診断方法の進歩などの要因によるものです。cfDNA検査は、がんに関連する遺伝子変異を、しばしば症状が現れる前の早い段階で検出します。この早期発見によってタイムリーな介入が可能になり、がんを初期段階で特定することで患者の転帰と生存率が向上します。例えば、2024年2月、世界保健機関（WHO）は、2050年までに新たに発生するがん患者数が3,500万人を超えると予測し、これは2022年の推定患者数2,000万人から77％増加することを示しています。したがって、がんの有病率の増加が無細胞DNA（cfDNA）検査市場の成長を促進しています。

無細胞DNA（cfDNA）検査市場の主なプレーヤーは、がんに関連する変異や遺伝子の変化を検出する感度、特異性、効率性を高めたリキッドバイオプシー検査などの革新的技術の開発を優先しています。リキッドバイオプシー検査は、腫瘍医が腫瘍細胞から放出される循環遊離DNAを評価できるようにする診断手順であり、個別化された標的治療戦略を促進します。例えば、米国のライフサイエンス企業であるラボラトリー・コーポレーション・オブ・アメリカ・ホールディングス（Labcorp）は2023年5月、進行性または転移性の固形がん患者向けに調整された新しいリキッドバイオプシー検査であるLabcorp Plasma Focusを発表しました。この検査は、標準的な採血により腫瘍細胞から採取した循環遊離DNA（cfDNA）を評価するもので、侵襲を最小限に抑え、迅速に結果を得ることができます。この検査は、非小細胞肺がん、大腸がん、乳がん、食道がん、胃食道接合部がん、胃がん、メラノーマなど、一般的なさまざまながんにおける臨床的に実用的なバイオマーカーを同定することにより、プレシジョン・オンコロジーへのアクセスを向上させる。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、新型コロナウイルス感染症、そして景気回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界細胞遊離DNA（cfDNA）検査PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の細胞遊離DNA（cfDNA）検査市場：成長率分析
• 世界の細胞遊離DNA（cfDNA）検査市場の実績：規模と成長, 2019-2024
• 世界の細胞遊離DNA（cfDNA）検査市場の予測：規模と成長, 2024-2029, 2034F
• 世界細胞遊離DNA（cfDNA）検査総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の細胞遊離DNA（cfDNA）検査市場：製品別、実績と予測, 2019-2024, 2024-2029F, 2034F
• ドナー由来遊離DNA
• 循環遊離細胞腫瘍DNA
• 遊離胎児DNA
• 世界の細胞遊離DNA（cfDNA）検査市場プラットフォーム別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 次世代シーケンシング（NGS）
• rPCRとマルチプレックスPCR
• qPCRとdPCR
• その他のプラットフォーム
• 世界の細胞遊離DNA（cfDNA）検査市場：用途別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 腫瘍学
• 非侵襲的出生前検査（NIPT）
• 婦人科
• 移植
• その他の用途
• 世界の細胞遊離DNA（cfDNA）検査市場ドナー由来遊離DNAの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 臓器移植モニタリング
• 移植片拒絶反応の検出
• 世界の細胞遊離DNA（cfDNA）検査市場循環遊離細胞腫瘍DNAの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• がん検出
• 微小残存病変モニタリング
• 液体生検
• 世界の細胞遊離DNA（cfDNA）検査市場遊離胎児DNAのサブセグメンテーション（タイプ別）、実績と予測, 2019-2024, 2024-2029F, 2034F
• 非侵襲的出生前検査（NIPT）
• 胎児遺伝性疾患スクリーニング

第7章 地域別・国別分析

• 世界の細胞遊離DNA（cfDNA）検査市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の細胞遊離DNA（cfDNA）検査市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 細胞遊離DNA（cfDNA）検査市場：競合情勢
• 細胞遊離DNA（cfDNA）検査市場：企業プロファイル
  • F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Laboratory Corporation of America Holdings Overview, Products and Services, Strategy and Financial Analysis
  • Quest Diagnostics Incorporated Overview, Products and Services, Strategy and Financial Analysis
  • Agilent Technologies Inc. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Illumina Inc.
• Qiagen N.V.
• Exact Sciences Corporation
• Bio-Techne Corporation
• Natera Inc.
• Myriad Genetics Inc.
• NeoGenomics Laboratories Inc.
• Invitae Corporation
• Foundation Medicine Inc.
• Guardant Health Inc.
• Integrated DNA Technologies Inc.
• Caris Life Sciences Inc.
• Twist Bioscience Corporation
• Adaptive Biotechnologies Corporation
• Biodesix Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 細胞遊離DNA（cfDNA）検査市場2029：新たな機会を提供する国
• 細胞遊離DNA（cfDNA）検査市場2029：新たな機会を提供するセグメント
• 細胞遊離DNA（cfDNA）検査市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Cell-free DNA (cfDNA) testing is a non-invasive diagnostic technique that examines DNA fragments freely circulating in the bloodstream. This testing method is integral to liquid biopsy procedures, enabling the detection and analysis of genetic mutations and alterations without resorting to traditional tissue biopsies.

The primary products within the cell-free DNA (cfDNA) testing market include donor-derived cell-free DNA, circulating cell-free tumor DNA, and cell-free fetal DNA. Donor-derived cell-free DNA originates from transplanted donor organs or tissues and can be found in the recipient's bloodstream. Various platforms are utilized for cfDNA testing, such as next-generation sequencing (NGS), real-time PCR (rPCR) and multiplex PCR, quantitative PCR (qPCR) and digital PCR (dPCR), among others. These platforms are applied across various domains including oncology, non-invasive prenatal testing (NIPT), gynecology, transplantation, and other medical conditions.

The cell-free DNA (cfDNA) testing market research report is one of a series of new reports from The Business Research Company that provides cell-free DNA (cfDNA) testing market statistics, including cell-free DNA (cfDNA) testing industry global market size, regional shares, competitors with a cell-free DNA (cfDNA) testing market share, detailed cell-free DNA (cfDNA) testing market segments, market trends, and opportunities, and any further data you may need to thrive in the cell-free DNA (cfDNA) testing industry. This cell-free DNA (cfDNA) testing research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The cell free dna (cfDNA) testing market size has grown exponentially in recent years. It will grow from $8.74 billion in 2024 to $10.86 billion in 2025 at a compound annual growth rate (CAGR) of 24.2%. The growth in the historic period can be attributed to a rise in the adoption of cfDNA testing in prenatal care, increasing use of cfDNA analysis, growing interest in cfDNA research across various medical fields, and rise in gaining approvals from regulatory bodies.

The cell free dna (cfDNA) testing market size is expected to see exponential growth in the next few years. It will grow to $25.56 billion in 2029 at a compound annual growth rate (CAGR) of 23.9%. The growth in the forecast period can be attributed to a shift towards personalized medicine, enhancements in healthcare infrastructure, aging population and increasing incidence of cancer, increasing adoption of precision medicine, increasing awareness and acceptance of liquid biopsy techniques, and increasing investment and funding in cfDNA research. Major trends in the forecast period include adoption of liquid biopsy technologies, advancements in Next-Generation Sequencing (NGS) technology, integration of AI and machine learning in cfDNA testing, development of point-of-care cfDNA tests, and implementation of cloud-based platforms for data storage and analysis.

The increasing prevalence of cancer is expected to drive the growth of the cell-free DNA (cfDNA) testing market in the future. Cancer encompasses a complex group of diseases characterized by abnormal cell growth and spread in the body. These cells can invade and damage normal tissue, posing significant risks if left unchecked. The rise in cancer prevalence is attributed to factors such as aging populations, lifestyle changes, environmental influences, and advancements in detection and diagnostic methods. cfDNA testing detects genetic mutations linked to cancer at early stages, often before symptoms manifest. This early detection enables timely interventions, enhancing patient outcomes and survival rates by identifying cancer in its initial phases. For example, in February 2024, the World Health Organization (WHO) projected over 35 million new cancer cases by 2050, marking a 77% increase from the estimated 20 million cases in 2022. Hence, the increasing prevalence of cancer is fueling the growth of the cell-free DNA (cfDNA) testing market.

Key players in the cell-free DNA (cfDNA) testing market prioritize the development of innovative technologies, such as liquid biopsy tests that offer heightened sensitivity, specificity, and efficiency in detecting cancer-related mutations and genetic changes. Liquid biopsy tests involve diagnostic procedures enabling oncologists to assess circulating cell-free DNA released by tumor cells, facilitating personalized and targeted therapy strategies. For instance, in May 2023, Laboratory Corporation of America Holdings (Labcorp), a US-based life sciences company, introduced Labcorp Plasma Focus, a new liquid biopsy test tailored for patients with advanced or metastatic solid tumors. This test evaluates circulating cell-free DNA (cfDNA) from tumor cells through a standard blood draw, ensuring minimal invasiveness and rapid results. It enhances access to precision oncology by identifying clinically actionable biomarkers across various common cancers such as non-small cell lung, colorectal, breast, esophageal, gastroesophageal junction, gastric cancers, and melanoma.

In February 2022, Laboratory Corporation of America Holdings (LabCorp), a US-based clinical healthcare company, acquired Personal Genome Diagnostics Inc. for an undisclosed sum. This acquisition positions LabCorp to advance its existing liquid biopsy capabilities and broaden its array of state-of-the-art next-generation sequencing (NGS)-based genomic profiling tools for cancer, positioning it at the forefront of improving patient outcomes. Personal Genome Diagnostics Inc. specializes in precision oncology diagnostics, including cell-free DNA testing technology.

Major companies operating in the cell free DNA (CFDNA) testing market are F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Laboratory Corporation of America Holdings, Quest Diagnostics Incorporated, Agilent Technologies Inc., Illumina Inc., Qiagen N.V., Exact Sciences Corporation, Bio-Techne Corporation, Natera Inc., Myriad Genetics Inc., NeoGenomics Laboratories Inc., Invitae Corporation, Foundation Medicine Inc., Guardant Health Inc., Integrated DNA Technologies Inc., Caris Life Sciences Inc., Twist Bioscience Corporation, Adaptive Biotechnologies Corporation, Biodesix Inc., Biocept Inc., Personal Genome Diagnostics Inc., Agena Bioscience Inc., Menarini Silicon Biosystems Inc., Circulogene Theranostics LLC

North America was the largest region in the cell-free DNA (CFDNA) testing market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cell free DNA (CFDNA)) testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the cell free DNA (CFDNA) testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The cell-free DNA (cfDNA) testing market consists of revenue entities earned by providing services such as liquid biopsy for cancer detection and monitoring, transplant rejection monitoring, and non-invasive prenatal testing. The market value includes the value of related goods sold by the service provider or included within the service offering. The cell-free DNA (cfDNA) testing market also includes sales of products such as digital PCR systems, automated nucleic acid extraction systems, real-time PCR instruments, and library preparation systems for NGS. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Cell Free DNA (cfDNA) Testing Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on cell free dna (cfdna) testing market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for cell free dna (cfdna) testing ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The cell free dna (cfdna) testing market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Product: Donor-Derived Cell-Free DNA; Circulating Cell-Free Tumor DNA; Cell-Free Fetal DNA
• 2) By Platforms: Next Generation Sequencing (NGS); rPCR And Multiplexed PCR; qPCR And dPCR; Other platforms
• 3) By Application: Oncology; Non-Invasive Prenatal Test (NIPT); Gynecology; Transplantation; Other Applications
• Subsegments:
• 1) By Donor-Derived Cell-Free DNA: Organ Transplant Monitoring; Graft Rejection Detection
• 2) By Circulating Cell-Free Tumor DNA: Cancer Detection; Minimal Residual Disease Monitoring; Liquid Biopsy
• 3) By Cell-Free Fetal DNA: Non-Invasive Prenatal Testing (NIPT); Fetal Genetic Disorder Screening
• Companies Mentioned: F. Hoffmann-La Roche Ltd.; Thermo Fisher Scientific Inc.; Laboratory Corporation of America Holdings; Quest Diagnostics Incorporated; Agilent Technologies Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Cell Free DNA (cfDNA) Testing Market Characteristics

3. Cell Free DNA (cfDNA) Testing Market Trends And Strategies

4. Cell Free DNA (cfDNA) Testing Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Cell Free DNA (cfDNA) Testing Growth Analysis And Strategic Analysis Framework

• 5.1. Global Cell Free DNA (cfDNA) Testing PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Cell Free DNA (cfDNA) Testing Market Growth Rate Analysis
• 5.4. Global Cell Free DNA (cfDNA) Testing Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Cell Free DNA (cfDNA) Testing Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Cell Free DNA (cfDNA) Testing Total Addressable Market (TAM)

6. Cell Free DNA (cfDNA) Testing Market Segmentation

• 6.1. Global Cell Free DNA (cfDNA) Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Donor-Derived Cell-Free DNA
• Circulating Cell-Free Tumor DNA
• Cell-Free Fetal DNA
• 6.2. Global Cell Free DNA (cfDNA) Testing Market, Segmentation By Platforms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Next Generation Sequencing (NGS)
• rPCR and Multiplexed PCR
• qPCR and dPCR
• Other Platforms
• 6.3. Global Cell Free DNA (cfDNA) Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oncology
• Non-Invasive Prenatal Test (NIPT)
• Gynecology
• Transplantation
• Other Applications
• 6.4. Global Cell Free DNA (cfDNA) Testing Market, Sub-Segmentation Of Donor-Derived Cell-Free DNA, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Organ Transplant Monitoring
• Graft Rejection Detection
• 6.5. Global Cell Free DNA (cfDNA) Testing Market, Sub-Segmentation Of Circulating Cell-Free Tumor DNA, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Cancer Detection
• Minimal Residual Disease Monitoring
• Liquid Biopsy
• 6.6. Global Cell Free DNA (cfDNA) Testing Market, Sub-Segmentation Of Cell-Free Fetal DNA, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Non-Invasive Prenatal Testing (NIPT)
• Fetal Genetic Disorder Screening

7. Cell Free DNA (cfDNA) Testing Market Regional And Country Analysis

• 7.1. Global Cell Free DNA (cfDNA) Testing Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Cell Free DNA (cfDNA) Testing Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Cell Free DNA (cfDNA) Testing Market

• 8.1. Asia-Pacific Cell Free DNA (cfDNA) Testing Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Cell Free DNA (cfDNA) Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Cell Free DNA (cfDNA) Testing Market, Segmentation By Platforms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Cell Free DNA (cfDNA) Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Cell Free DNA (cfDNA) Testing Market

• 9.1. China Cell Free DNA (cfDNA) Testing Market Overview
• 9.2. China Cell Free DNA (cfDNA) Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Cell Free DNA (cfDNA) Testing Market, Segmentation By Platforms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Cell Free DNA (cfDNA) Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Cell Free DNA (cfDNA) Testing Market

• 10.1. India Cell Free DNA (cfDNA) Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Cell Free DNA (cfDNA) Testing Market, Segmentation By Platforms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Cell Free DNA (cfDNA) Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Cell Free DNA (cfDNA) Testing Market

• 11.1. Japan Cell Free DNA (cfDNA) Testing Market Overview
• 11.2. Japan Cell Free DNA (cfDNA) Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Cell Free DNA (cfDNA) Testing Market, Segmentation By Platforms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Cell Free DNA (cfDNA) Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Cell Free DNA (cfDNA) Testing Market

• 12.1. Australia Cell Free DNA (cfDNA) Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Cell Free DNA (cfDNA) Testing Market, Segmentation By Platforms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Cell Free DNA (cfDNA) Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Cell Free DNA (cfDNA) Testing Market

• 13.1. Indonesia Cell Free DNA (cfDNA) Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Cell Free DNA (cfDNA) Testing Market, Segmentation By Platforms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Cell Free DNA (cfDNA) Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Cell Free DNA (cfDNA) Testing Market

• 14.1. South Korea Cell Free DNA (cfDNA) Testing Market Overview
• 14.2. South Korea Cell Free DNA (cfDNA) Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Cell Free DNA (cfDNA) Testing Market, Segmentation By Platforms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Cell Free DNA (cfDNA) Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Cell Free DNA (cfDNA) Testing Market

• 15.1. Western Europe Cell Free DNA (cfDNA) Testing Market Overview
• 15.2. Western Europe Cell Free DNA (cfDNA) Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Cell Free DNA (cfDNA) Testing Market, Segmentation By Platforms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Cell Free DNA (cfDNA) Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Cell Free DNA (cfDNA) Testing Market

• 16.1. UK Cell Free DNA (cfDNA) Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Cell Free DNA (cfDNA) Testing Market, Segmentation By Platforms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Cell Free DNA (cfDNA) Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Cell Free DNA (cfDNA) Testing Market

• 17.1. Germany Cell Free DNA (cfDNA) Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Cell Free DNA (cfDNA) Testing Market, Segmentation By Platforms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Cell Free DNA (cfDNA) Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Cell Free DNA (cfDNA) Testing Market

• 18.1. France Cell Free DNA (cfDNA) Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Cell Free DNA (cfDNA) Testing Market, Segmentation By Platforms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Cell Free DNA (cfDNA) Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Cell Free DNA (cfDNA) Testing Market

• 19.1. Italy Cell Free DNA (cfDNA) Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Cell Free DNA (cfDNA) Testing Market, Segmentation By Platforms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Cell Free DNA (cfDNA) Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Cell Free DNA (cfDNA) Testing Market

• 20.1. Spain Cell Free DNA (cfDNA) Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Cell Free DNA (cfDNA) Testing Market, Segmentation By Platforms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Cell Free DNA (cfDNA) Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Cell Free DNA (cfDNA) Testing Market

• 21.1. Eastern Europe Cell Free DNA (cfDNA) Testing Market Overview
• 21.2. Eastern Europe Cell Free DNA (cfDNA) Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Cell Free DNA (cfDNA) Testing Market, Segmentation By Platforms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Cell Free DNA (cfDNA) Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Cell Free DNA (cfDNA) Testing Market

• 22.1. Russia Cell Free DNA (cfDNA) Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Cell Free DNA (cfDNA) Testing Market, Segmentation By Platforms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Cell Free DNA (cfDNA) Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Cell Free DNA (cfDNA) Testing Market

• 23.1. North America Cell Free DNA (cfDNA) Testing Market Overview
• 23.2. North America Cell Free DNA (cfDNA) Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Cell Free DNA (cfDNA) Testing Market, Segmentation By Platforms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Cell Free DNA (cfDNA) Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Cell Free DNA (cfDNA) Testing Market

• 24.1. USA Cell Free DNA (cfDNA) Testing Market Overview
• 24.2. USA Cell Free DNA (cfDNA) Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Cell Free DNA (cfDNA) Testing Market, Segmentation By Platforms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Cell Free DNA (cfDNA) Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Cell Free DNA (cfDNA) Testing Market

• 25.1. Canada Cell Free DNA (cfDNA) Testing Market Overview
• 25.2. Canada Cell Free DNA (cfDNA) Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Cell Free DNA (cfDNA) Testing Market, Segmentation By Platforms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Cell Free DNA (cfDNA) Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Cell Free DNA (cfDNA) Testing Market

• 26.1. South America Cell Free DNA (cfDNA) Testing Market Overview
• 26.2. South America Cell Free DNA (cfDNA) Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Cell Free DNA (cfDNA) Testing Market, Segmentation By Platforms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Cell Free DNA (cfDNA) Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Cell Free DNA (cfDNA) Testing Market

• 27.1. Brazil Cell Free DNA (cfDNA) Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Cell Free DNA (cfDNA) Testing Market, Segmentation By Platforms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Cell Free DNA (cfDNA) Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Cell Free DNA (cfDNA) Testing Market

• 28.1. Middle East Cell Free DNA (cfDNA) Testing Market Overview
• 28.2. Middle East Cell Free DNA (cfDNA) Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Cell Free DNA (cfDNA) Testing Market, Segmentation By Platforms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Cell Free DNA (cfDNA) Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Cell Free DNA (cfDNA) Testing Market

• 29.1. Africa Cell Free DNA (cfDNA) Testing Market Overview
• 29.2. Africa Cell Free DNA (cfDNA) Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Cell Free DNA (cfDNA) Testing Market, Segmentation By Platforms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Cell Free DNA (cfDNA) Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Cell Free DNA (cfDNA) Testing Market Competitive Landscape And Company Profiles

• 30.1. Cell Free DNA (cfDNA) Testing Market Competitive Landscape
• 30.2. Cell Free DNA (cfDNA) Testing Market Company Profiles
  • 30.2.1. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Laboratory Corporation of America Holdings Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Quest Diagnostics Incorporated Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Agilent Technologies Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Cell Free DNA (cfDNA) Testing Market Other Major And Innovative Companies

• 31.1. Illumina Inc.
• 31.2. Qiagen N.V.
• 31.3. Exact Sciences Corporation
• 31.4. Bio-Techne Corporation
• 31.5. Natera Inc.
• 31.6. Myriad Genetics Inc.
• 31.7. NeoGenomics Laboratories Inc.
• 31.8. Invitae Corporation
• 31.9. Foundation Medicine Inc.
• 31.10. Guardant Health Inc.
• 31.11. Integrated DNA Technologies Inc.
• 31.12. Caris Life Sciences Inc.
• 31.13. Twist Bioscience Corporation
• 31.14. Adaptive Biotechnologies Corporation
• 31.15. Biodesix Inc.

32. Global Cell Free DNA (cfDNA) Testing Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Cell Free DNA (cfDNA) Testing Market

34. Recent Developments In The Cell Free DNA (cfDNA) Testing Market

35. Cell Free DNA (cfDNA) Testing Market High Potential Countries, Segments and Strategies

• 35.1 Cell Free DNA (cfDNA) Testing Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Cell Free DNA (cfDNA) Testing Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Cell Free DNA (cfDNA) Testing Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer